Active substance
Cyanocobalamin
- SFDA 4
- US FDA 46
- US price lines 9
- NHS prices 2
- Safety 7
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| CYNOVIT 1MG-1ML I.M. Injection* | 1 mg | Injection · Intramuscular use | 5 Ampoule | SAR 7.35 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Valid |
| BETOLVEX INJ 1MG | 1 mg | Solution · Intramuscular use | 1 Ampoule | SAR 16.70 | Generic · Prescription | XELLIA PHARMACEUTICAL APS | Withdrawn by MAH · Not Marketed |
| CYTOBION | 1 mg | Injection · Intramuscular use | 3 Ampoule | SAR 19.65 | Generic · Prescription | Merck Healthcare KGaA | Withdrawn by MAH · Not Marketed |
| JECTIN-12 Solution For Injection | 1 mg | Solution for injection · Intramuscular use | 5 Ampoule | SAR 7.35 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
BARIATRIC SURGERY; NON-SMALL-CELL LUNG CARCINOMA (NSCLC); T-CELL LYMPHOMA; VITAMIN B12 DEFICENCY ANEMIA
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| CYANOCOBALAMIN | 1MG/ML | injectable · injection | WEST-WARD PHARMS INT | Prescription | 20 Oct 1971 |
| CYANOCOBALAMIN | 1MG/ML | injectable · injection | AM REGENT | Prescription | 26 Apr 1972 |
| VIBISONE | 1MG/ML | injectable · injection | FRESENIUS KABI USA | Prescription | 20 Jun 1973 |
| CYANOCOBALAMIN | 1MG/ML | injectable · injection | SOMERSET THERAPS LLC | Prescription | 11 Dec 2015 |
| CYANOCOBALAMIN | 1MG/ML | injectable · injection | H2-PHARMA | Prescription | 18 Dec 2018 |
| CYANOCOBALAMIN | 1MG/ML | injectable · injection | SOMERSET THERAPS LLC | Prescription | 18 Dec 2018 |
| CYANOCOBALAMIN | 0.5MG/SPRAY | spray, metered · nasal | PADAGIS ISRAEL | Prescription | 9 Sep 2020 |
| CYANOCOBALAMIN | 1MG/ML | injectable · injection | GLAND | Prescription | 24 Sep 2020 |
| CYANOCOBALAMIN | 1MG/ML | injectable · injection | EUGIA PHARMA | Prescription | 8 Dec 2020 |
| CYANOCOBALAMIN | 1MG/ML | injectable · injection | SANDOZ | Prescription | 4 Jan 2021 |
| CYANOCOBALAMIN | 1MG/ML | injectable · injection | ZYDUS PHARMS | Prescription | 15 Apr 2022 |
| CYANOCOBALAMIN | 1MG/ML | injectable · injection | SOLA PHARMS | Prescription | 15 Apr 2022 |
| CYANOCOBALAMIN | 1MG/ML | injectable · injection | SAGENT PHARMS INC | Prescription | 15 Nov 2022 |
| CYANOCOBALAMIN | 0.5MG/SPRAY | spray, metered · nasal | LUPIN | Prescription | 30 Jun 2023 |
| CYANOCOBALAMIN | 1MG/ML | injectable · injection | MANKIND PHARMA | Prescription | 10 Jul 2024 |
| CYANOCOBALAMIN | 1MG/ML | injectable · injection | MEITHEAL | Prescription | 15 Nov 2024 |
| CYANOCOBALAMIN | 1MG/ML | injectable · injection | ASPIRO | Prescription | 8 Jul 2026 |
| VI-TWEL | 1MG/ML | injectable · injection | BAYER HLTHCARE | Discontinued | 15 Sep 1949 |
| CYANOCOBALAMIN | 1MG/ML | injectable · injection | WARNER CHILCOTT | Discontinued | 6 Dec 1949 |
| RUBRAMIN PC | 0.1MG/ML; 1MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | injectable · injection | BRISTOL MYERS SQUIBB | Discontinued | 29 Sep 1950 |
| RUBIVITE | 0.05MG/ML; 0.1MG/ML; 1MG/ML; 0.03MG/ML; 0.12MG/ML | injectable · injection | BEL MAR | Discontinued | 14 Jul 1958 |
| DODEX | 1MG/ML | injectable · injection | ACCORD HLTHCARE | Discontinued | 20 Sep 1972 |
| CYANOCOBALAMIN | 0.1MG/ML; 1MG/ML | injectable · injection | WYETH AYERST | Discontinued | 21 Mar 1973 |
| CYANOCOBALAMIN | 0.1MG/ML | injectable · injection | FRESENIUS KABI USA | Discontinued | 20 Jun 1973 |
| CYANOCOBALAMIN | 0.03MG/ML; 0.1MG/ML; 1MG/ML | injectable · injection | DELL LABS | Discontinued | 22 Jun 1973 |
21 more — full table
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | CYANOCOBALAMIN 1,000 MCG/ML VL | $1.47387 | per ML | 23 Sep 2026 |
| US NADAC | CYANOCOBALAMIN 1,000 MCG/ML VL | $2.97018 | per ML | 23 Sep 2026 |
| US NADAC | CYANOCOBALAMIN 10,000 MCG/10 ML | $2.97018 | per ML | 23 Sep 2026 |
| US NADAC | CYANOCOBALAMIN 10,000 MCG/10 ML | $0.73861 | per ML | 23 Sep 2026 |
| US NADAC | CYANOCOBALAMIN 10,000 MCG/10 ML | $2.13372 | per ML | 23 Sep 2026 |
| US NADAC | CYANOCOBALAMIN 30,000 MCG/30 ML | $0.78707 | per ML | 23 Sep 2026 |
| US NADAC | CYANOCOBALAMIN 30,000 MCG/30 ML | $0.32805 | per ML | 18 Feb 2026 |
| US NADAC | CYANOCOBALAMIN 30,000 MCG/30 ML | $0.55247 | per ML | 23 Sep 2026 |
| US NADAC | CYANOCOBALAMIN 500 MCG SPRAY | $95.90838 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Cyanocobalamin 1mg tablets | £9.99 | 30 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Cyanocobalamin 50microgram tablets | £2.71 | 50 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 6 Nov 2024 INFUVITE ADULT — safety-related labeling change
Labeling sections changed: Use in Specific Populations - US FDA 6 Nov 2024 INFUVITE PEDIATRIC — safety-related labeling change
Labeling sections changed: Use in Specific Populations - US FDA 16 Dec 2020 M.V.I. ADULT — safety-related labeling change
Labeling sections changed: Contraindications; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 16 Jan 2020 CALOMIST — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Use in Specific Populations - US FDA 7 Dec 2018 NASCOBAL — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 9 Nov 2017 M.V.I. ADULT (PHARMACY BULK PACKAGE) — safety-related labeling change
Labeling sections changed: Contraindications; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 9 Nov 2017 M.V.I.-12 — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Combinations containing Cyanocobalamin
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.